Filing Flows › Companies › Twist Bioscience › Report card
Twist Bioscience earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 4 reports beat the EPS estimate
Twist Bioscience (TWST) beat the analysts' EPS estimate in 2 of its last 4 reports (50%), by -24.3% on average. On report days the stock moved 11.5% in either direction on median (largest 12.8%), rising 50% of the time. Next report: Nov 12, 2026, analysts expect EPS −$0.20.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS | Revenue guided | Revenue reported | Stock, the day | vs market |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY26 | Aug 3, 2026 | −$0.28 | −$0.56 | -98.5% | −$0.56 | $114M–$115M | $118M (above) | +8.6% | +5.4% |
| Q2 FY26 | May 4, 2026 | −$0.53 | −$0.60 | -12.6% | −$0.71 | — | $111M | -6.1% | -6.6% |
| Q1 FY26 | Feb 2, 2026 | −$0.52 | −$0.50 | +3.8% | −$0.50 | $100M–$101M | $104M (above) | +12.8% | +13.1% |
| Q4 FY25 | Nov 14, 2025 | −$0.50 | −$0.45 | +10.0% | — | — | $99.0M | -11.5% | -10.6% |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). Revenue guided is the last range the company gave before the report. Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.
Charts
The earnings-day move
Over 4 reports the stock moved 11.5% on median on the day (close to close), the largest move 12.8%.
How credible is its guidance?
Revenue: of 5 guided periods, 5 came in beyond the top end of the range, 0 within and 0 short of it; 5 of 5 on the better side of the midpoint, on average +2.1% against the midpoint (+ is better). Guidance has been conservative: results beat the range itself. On that record the odds the next lands on the better side of the midpoint are about 86%.
Position in the range: 0 is the worse end, 1 the better end (for costs and tax rates, lower). Odds are the record plus one each way (Laplace), not a forecast.
The next report: what to expect → Twist Bioscience: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.